MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Operating Cash Flow 2011-2026 | NVTA
Annual Operating Cash Flow Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -493 M | -560 M | -299 M | -145 M | -92.2 M | -98 M | -76.3 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -76.3 M | -560 M | -252 M |
Quarterly Operating Cash Flow Invitae Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -34.4 M | - | -411 M | -282 M | -148 M | - | -384 M | -219 M | -89.5 M | - | -185 M | -123 M | -62.4 M | - | -97.8 M | -61.1 M | -28.4 M | - | -76.7 M | -58.7 M | -32.9 M | - | -66.7 M | -41.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -28.4 M | -411 M | -133 M |
Operating Cash Flow of other stocks in the Diagnostics research industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-21.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
CareDx, Inc
CDNA
|
42 M | $ 17.82 | - | $ 950 M |  USA |
 |
Agilent Technologies
A
|
1.48 B | $ 114.84 | - | $ 34.9 B | USA |
 |
Co-Diagnostics
CODX
|
-29.1 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
738 M | $ 168.22 | - | $ 8.34 B | USA |
 |
Castle Biosciences
CSTL
|
64.9 M | $ 24.73 | - | $ 687 M | USA |
 |
Danaher Corporation
DHR
|
6.42 B | $ 192.12 | - | $ 137 B | USA |
 |
DexCom
DXCM
|
1.44 B | $ 63.21 | - | $ 24.7 B | USA |
 |
Fulgent Genetics
FLGT
|
21.1 M | $ 16.42 | -2.38 % | $ 496 M | USA |
 |
Guardant Health
GH
|
-185 M | $ 89.66 | - | $ 11.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.29 B | $ 109.62 | - | $ 9.04 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
5.83 M | $ 1.97 | - | $ 8.72 M | USA |
 |
Illumina
ILMN
|
837 M | $ 127.74 | - | $ 20.3 B | USA |
|
Akumin
AKU
|
65.4 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Laboratory Corporation of America Holdings
LH
|
1.64 B | $ 274.46 | - | $ 22.8 B | USA |
 |
Lantheus Holdings
LNTH
|
390 M | $ 75.89 | - | $ 5.12 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
-478 M | $ 16.3 | - | $ 175 M |  China |
 |
Medpace Holdings
MEDP
|
713 M | $ 496.0 | - | $ 14.3 B | USA |
 |
Aspira Women's Health
AWH
|
-7.03 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-48.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
Myriad Genetics
MYGN
|
1.8 M | $ 4.67 | - | $ 432 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-5.18 M | $ 4.74 | 1.07 % | $ 3.73 M | USA |
 |
NeoGenomics
NEO
|
5.23 M | $ 8.02 | - | $ 1.03 B | USA |
 |
Neogen Corporation
NEOG
|
58.2 M | $ 9.56 | - | $ 2.07 B | USA |
 |
National Research Corporation
NRC
|
26.4 M | $ 17.33 | - | $ 388 M | USA |
 |
Natera
NTRA
|
-432 M | $ 204.87 | - | $ 20.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
614 M | - | - | $ 399 M | China |
 |
Pacific Biosciences of California
PACB
|
-111 M | $ 1.42 | - | $ 426 M | USA |
 |
Genetic Technologies Limited
GENE
|
-5.66 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-524 M | - | 0.12 % | $ 80.1 M | China |
 |
Precipio
PRPO
|
685 K | $ 25.98 | 2.28 % | $ 41.7 M | USA |
 |
Personalis
PSNL
|
-45.2 M | $ 6.58 | - | $ 390 M | USA |
 |
Sotera Health Company
SHC
|
287 M | $ 14.87 | - | $ 4.22 B | USA |
 |
Soleno Therapeutics
SLNO
|
46.8 M | $ 52.25 | - | $ 2.66 B | USA |
 |
Biocept
BIOC
|
-13.3 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
-20.4 M | $ 1.76 | - | $ 116 M | USA |
|
Biodesix
BDSX
|
-48.6 M | $ 15.36 | - | $ 1.99 B | USA |
 |
Thermo Fisher Scientific
TMO
|
7.82 B | $ 488.19 | - | $ 184 B | USA |
 |
Trinity Biotech plc
TRIB
|
13.2 M | $ 0.62 | - | $ 61.9 M | Irlanda |
 |
VolitionRx Limited
VNRX
|
-19.7 M | $ 0.17 | - | $ 21.4 M |  Singapore |
 |
Waters Corporation
WAT
|
653 M | $ 304.09 | - | $ 18.1 B | USA |
 |
Exagen
XGN
|
-13.6 M | $ 3.08 | - | $ 66.4 M | USA |
 |
QIAGEN N.V.
QGEN
|
654 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
-7.17 M | $ 2.59 | - | $ 84.1 K | USA |
 |
Biomerica
BMRA
|
-3.84 M | $ 2.17 | - | $ 4.98 M | USA |
 |
BioNano Genomics
BNGO
|
-16.3 M | $ 1.15 | - | $ 6.26 M | USA |